Drug Trial Radar · NCT04959032
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
592
Actual
Start
Jul 8, 2021
Primary completion
Jul 25, 2024
Study completion Aug 7, 2024
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).
Conditions
- Schizophrenia
Interventions
Lumateperone 42 mgDrug
Lumateperone 42 mg capsules administered orally, once daily.
PlaceboDrug
Matching capsules administered orally, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Symptom Relapse During the Double-blind Treatment PhaseTime frame: Number of days from the randomization date to the first relapse date up to 26 weeks.
Locations
43 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Site
Little Rock, Arkansas
Clinical Site
Bellflower, California
Clinical Site
Cerritos, California
Clinical Site
Culver City, California
Clinical Site
Garden Grove, California
Clinical Site
Lemon Grove, California
Clinical Site
Montclair, California
Clinical Site
Orange, California
Clinical Site
Hollywood, Florida
Clinical Site
Miami Lakes, Florida
Clinical Site
Oakland Park, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Chicago, Illinois
Clinical Site
Boston, Massachusetts
Clinical Site
St Louis, Missouri
Clinical Site
Las Vegas, Nevada
Clinical Site
Berlin, New Jersey
Clinical Site
North Canton, Ohio
Clinical Site
Austin, Texas
Clinical Site
DeSoto, Texas
Clinical Site
Richardson, Texas
Clinical Site
Burgas, Bulgaria
Clinical Site
Kardzhali, Bulgaria
Clinical Site
Kazanlak, Bulgaria
Clinical Site
Lovech, Bulgaria
Clinical Site
Novi Iskar, Bulgaria
Clinical Site
Pleven, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Rousse, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Targovishte, Bulgaria
Clinical Site
Tsarev Brod, Bulgaria
Clinical Site
Tserova Koria, Bulgaria
Clinical Site
Veliko Tarnovo, Bulgaria
Clinical Site
Vratsa, Bulgaria
Clinical Site
Gdansk, Poland
Clinical Site
Gdansk, Poland
Clinical Site
Gorlice, Poland
Clinical Site
Tuszyn, Poland
Clinical site
Belgrade, Serbia
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.